

True.

Blue.



 **Mitigare**[®]
(colchicine) Capsules

True.

It's True. Mitigare® and its authorized generic colchicine 0.6 mg capsules may help make gout flare prevention affordable.

It's True. When your doctor prescribes Mitigare®, your pharmacist can dispense its authorized generic, which may help you save money.

It's True. The Mitigare® True Blue Savings program* may help you save even more.

It's True. Colchicine has been used for gout flare prevention for hundreds of years.

It's True. West-Ward Pharmaceuticals launched the first authorized generic 0.6 mg colchicine capsules.

Blue.



It's Blue. The distinctive two-tone capsule may help patients identify their medication.¹

Please see Important Safety Information and Indication on back and accompanying Full Prescribing Information and Medication Guide.

* For all eligible patients 18 years or older who are legal residents of the United States or Puerto Rico. Please visit www.mitigare.com for more details on eligibility requirements.

Gout basics.

- It's a complex form of arthritis in which excess uric acid builds up over time. Symptoms may not occur for months, even years.
- Patients experience joint swelling, redness, warmth and pain—often in the big toe, but also in areas such as the heel, ankle, instep, knee, elbow, hip, thumb and fingers.
- In the more serious stages of gout, flares can happen more often, last longer and are more painful.
- Talk with your physician about how gout medication may interact with other medications you take. Patients with kidney and liver impairment should not take colchicine. The most common adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting and abdominal pain.

Ask your doctor about gout flare prevention for adults with Mitigare[®] (colchicine) 0.6 mg capsules today.

 **Mitigare[®]**
(colchicine) Capsules

True.

It's True. Mitigare® and its authorized generic colchicine 0.6 mg capsules may help make gout flare prevention affordable.

It's True. When your doctor prescribes Mitigare®, your pharmacist can dispense its authorized generic, which may help you save money.

It's True. The Mitigare® True Blue Savings program* may help you save even more.

It's True. Colchicine has been used for gout flare prevention for hundreds of years.

It's True. West-Ward Pharmaceuticals launched the first authorized generic 0.6 mg colchicine capsules.

Blue.



It's Blue. The distinctive two-tone capsule may help patients identify their medication.¹

Please see Important Safety Information and Indication on back and accompanying Full Prescribing Information and Medication Guide.

* For all eligible patients 18 years or older who are legal residents of the United States or Puerto Rico. Please visit www.mitigare.com for more details on eligibility requirements.

Gout flare prevention

- It's a complex condition that builds up over time, even years.
- Patients experience pain—often in the heel, ankle, or joint.
- In the morning, it often, leads to stiffness.
- Talk with your doctor about interactions with kidney disease, stomach issues, and vomiting.



First 30 days Free* | **\$5* refills**

Seeing blue may lead to saving green with Mitigare® True Blue Savings.

Patient/Caregiver:
Give this card to your pharmacist along with a valid prescription for the authorized generic colchicine 0.6 mg capsules or the brand Mitigare® (colchicine) 0.6 mg capsules.

Valid on the authorized generic colchicine 0.6 mg capsules (NDC 00143-3018-01) or the brand Mitigare® (NDC 59467-0318-01). Please refer to the back of this card for the program requirements and restrictions.

Pharmacist:
Submit claim to MedImpact for processing information. Validity period: 30 days.

Ask your doctor about gout flare prevention for adults with Mitigare® (colchicine) 0.6 mg capsules today.



Important Safety Information

- Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
- Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
- Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia and aplastic anemia have been reported with colchicine used in therapeutic doses.
- Monitor for toxicity and, if present, consider temporary interruption or discontinuation of colchicine.
- Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
- Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
- The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare® for acute treatment of gout flares during prophylaxis have not been studied. Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

Reference

1. White Paper—What is the Significance of the Color of a Pill. *Wallcur, LLC*. <http://www.wallcur.com/whitepaper-pill-color.aspx>. Accessed June 28, 2016.

Please see accompanying Full Prescribing Information and Medication Guide. Visit www.mitigare.com for more information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.